Alzheimer’s Dementia and Longevity: H2 Global Group Offers a Solution, Opens an Investment Window, and Moves Toward the Medicine of the Future
Alzheimer’s Dementia and Longevity: H2 Global Group Offers a Solution, Opens an Investment Window, and Moves Toward the Medicine of the Future
Prague, December 19, 2025 (PROTEXT) – Dementia and Alzheimer’s disease are rapidly becoming one of the most significant health, social, and economic challenges of our time—and even more so of the decades ahead. Alzheimer’s dementia is often referred to as the “cancer of the mind.” In its early stages, it does not progress dramatically from one day to the next, but rather slowly erodes memory, identity, and independence. The burden does not rest solely on patients, but also on their families, healthcare systems, and public budgets.
According to data from the World Health Organization, approximately 57 million people worldwide were living with dementia in 2021, with nearly 10 million new cases each year. Alzheimer’s disease accounts for roughly 60–70% of all dementia cases. At the same time, the economic burden is rising sharply. Alzheimer’s Disease International reports that global dementia-related costs already exceed USD 1.3 trillion annually and could reach USD 2.8 trillion per year by 2030. This is a challenge affecting virtually every country—and all of us.
Where Dementia Meets Longevity
This is where dementia intersects fundamentally with the concept of longevity. The desire to live longer alone is not enough. True longevity means extending the years of life spent in good health, and above all preserving a youthful mind—memory, focus, and independent decision-making. At this point, preventive longevity practice naturally converges with one of the greatest medical challenges of our time.
This is where the Czech group H2 Global Group enters the picture, building a hydrogen-based platform that connects longevity with medicine.
“We are not a pharmaceutical giant with unlimited resources. What we have is a unique, patent-protected, and scalable approach that brings new possibilities into medicine and has already attracted the attention of global players. We deliberately chose a financing path that allows even smaller investors to participate in the value growth of the project before key clinical milestones,”
says David Maršálek, Founder and CEO of H2 Global Group.
The Longevity Boom: One of the Largest Market Opportunities Today
The longevity market is currently experiencing an unprecedented investment boom. Estimates suggest that the global longevity market could reach USD 1.87 trillion by 2034. Capital is flowing into premium longevity and medical centers, biotechnology targeting aging processes, and concierge medicine—high-end personalized healthcare.
Successful projects share common traits: clinical credibility, measurable and visible outcomes, and scalable business models. It is precisely within this logic that H2 Global Group positions its hydrogen-based business as a bridge between the rapidly expanding longevity market and traditional medicine—leading toward the medicine of the future.
H2 Longevity as a New Standard: Prevention, Performance, and Healthy Aging
Longevity today represents a shift in how individuals, clinics, and service providers approach health—from “firefighting problems” toward long-term vitality, regeneration, resilience, and overall quality of life.
H2 Global Group has translated this trend into a practical, scalable model for both end customers and B2B partners, integrating it with molecular hydrogen technologies and know-how for safe real-world use. Today, the company works with a wide range of partners, including elite athletes and sports clubs, therapeutic spas, private medical and dental clinics, wellness hotels, and biohacking and longevity centers.
H2 Longevity® Lifestyle Ostrava: A Next-Generation Center Beyond Prevention
One of the most visible milestones this year was the opening of H2 Longevity® Ostrava, publicly presented as a next-generation healthy longevity center and a model showroom for customers, distributors, professional partners, and investors.
The center combines:
-
molecular hydrogen inhalation using H2 Medical Technologies devices,
-
light therapy,
-
hydrogen hydration via H2 Premium® Hydrogen Water,
-
specialized supplements such as H2 Brain® and H2 Forte®,
-
unique hydrogen-based cosmetics,
-
and education focused on regeneration and healthy aging.
The Ostrava center serves not only as a premium destination for end clients, but also as a reference point for future expansion through partners.
From Longevity to the Medicine of the Future via an Approved Clinical Study
A key transition is moving from prevention to data-driven medicine. Through its MedTech division H2 Medical Technologies, H2 Global Group announced that the State Institute for Drug Control (SÚKL) has approved the first clinical study in the Czech Republic evaluating the safety of molecular hydrogen inhalation in patients with mild cognitive impairment (MCI)—a condition often considered a precursor to Alzheimer’s dementia.
The study will use the first functional prototype of a molecular hydrogen-generating medical device developed by H2 Medical Technologies. It will begin in January 2026, last six months, and include approximately 30 patients aged 50–80, followed by a monitoring and data evaluation phase. Eligible participants may still apply (see details below).
Building on this approved study, the group’s next strategic ambition is the registration of the world’s first medical device based on molecular hydrogen. The initial focus is Alzheimer’s dementia—both prevention and supportive treatment—with potential expansion into other indications, including type 2 diabetes, vision and hearing disorders, dermatological conditions, and more.
This modular approach is also crucial for the partner ecosystem, enabling clinics and longevity providers to gradually expand their offerings—from regeneration and vitality to specialized adjunctive protocols.
Call for Participation in the Clinical Study
H2 Medical Technologies has issued a public call for volunteers who meet the following criteria:
-
age 50–80,
-
generally good health,
-
diagnosis of mild cognitive impairment or mild to moderate dementia,
-
preferably residence in Ostrava or the surrounding area.
Participation does not guarantee any health benefit and should not be considered a substitute for standard treatment.
Interested individuals may apply by January 19, 2026, via email:
📧 david.skoloudik@H2medical.com
A Patent That Turns a Molecule into a Platform
H2 Global Group continues to systematically build its intellectual property portfolio, anchored by the European patent EP3701956B1, “Prophylactic or Therapeutic Agent for Dementia,” authored by Professor Shigeo Ohta and held by H2 Global Group. The patent covers the use of molecular hydrogen in neurodegenerative diseases, including dementia, and is currently being expanded into additional global territories.
From an investment perspective, the critical factor is the combination of scientific foundation, patent protection, regulatory planning, and clinical data, which transforms a “simple molecule” into a scalable technological platform.
Toward Regulated Medicine: Clinical Data, Safety, and Responsibility
Scientific leadership toward regulated medicine is overseen by PharmDr. Milan Krajíček, Director of R&D at H2 Medical Technologies.
“Our solution represents a completely new, non-invasive, and safe method whose effects on neurodegenerative diseases are now being clinically tested,” he says, adding that launching a clinical study directly linked to Professor Ohta’s patent is both an honor and a responsibility.
Safety remains paramount. Professor MUDr. David Školoudík, Ph.D., the medical guarantor of the study, notes:
“The device produces hydrogen at a relatively low and safe concentration.”
From a Personal Story to International Ambition
Drawing on years of practical experience and studies at Dublin Business School, David Maršálek is now building an international technology platform in longevity and modern medicine.
Fourteen years have passed since his meeting in the U.S. with Professor Dušan Miljkovič, the scientist who introduced the world’s first hydrogen-based dietary supplement and became Maršálek’s first mentor. That encounter sparked a journey that evolved into a project with global ambitions.
Today, the team includes Professor Shigeo Ohta, researchers from Palacký University led by Assoc. Prof. Michal Botek, PharmDr. Milan Krajíček, MUDr. Pavel Malovič, PhD., MPH, and others—culminating in the formation of H2 Global Group and H2 Medical Technologies, focused on molecular hydrogen research and development in medicine.
Virtual Reality and Molecular Hydrogen: A Globally Unique Ecosystem
H2 Global Group has expanded into rehabilitation and psychology through a 20% equity stake in VR LIFE / VR Vitalis—one of Europe’s most advanced digital rehabilitation systems.
Since H2 Global Group’s entry:
-
therapeutic modules expanded from 22 to 52,
-
the solution achieved MDR medical device certification,
-
over 63,000 therapeutic sessions have been completed across the EU.
A unique aspect is the integration of regulated VR rehabilitation with molecular hydrogen inhalation, protected by a utility model and patent application.
“Virtual reality allows patients to fully immerse themselves in a guided environment, detach from external stressors, and focus on breathing and movement. When combined with molecular hydrogen inhalation, it creates a powerful space for mental balance, rehabilitation, and regeneration,”
explains Mgr. Jana Trdá, Ph.D., Co-Founder of VR LIFE.
The Investment Window Before Key Milestones
In MedTech, company valuations typically increase in steps, triggered by major milestones such as clinical trial initiation, data evaluation, or regulatory approvals.
H2 Global Group openly communicates its ambition to register the world’s first molecular hydrogen medical device and make it reimbursable through public health insurance systems—followed by expansion into additional indications.
Market history shows that regulatorily anchored platforms often become acquisition targets worth tens of billions of dollars—as demonstrated by transactions involving Medtronic, Abbott, Boston Scientific, BD, and Johnson & Johnson.
These examples confirm that extraordinary value arises when clinical data, regulatory credibility, scalable business models, and strong market positioning converge—precisely where H2 Global Group is now focusing.
This is why the current phase represents an attractive entry point for investors, ahead of key clinical and regulatory milestones—historically the moment of greatest upside potential.
A Strategic Call to Investors and Partners
H2 Global Group stands at the intersection of several global megatrends:
-
the rapidly growing longevity economy,
-
the escalating dementia crisis,
-
and the urgent need for measurable, safe, and clinically viable medical solutions.
For investors and partners, this moment resembles historic turning points in medicine—from antibiotics to breakthrough therapeutic platforms—where scientific discovery gave rise to entirely new industries.
“Every day we receive new inquiries from investors and partners around the world who see the opportunity to expand their portfolios with our hydrogen solutions,”
says David Maršálek.
“H2 Global Group is therefore opening space for investors, distributors, and strategic partners who want to help shape a new standard in longevity and the medicine of the future—before its full value is reflected in the global market.”